Daraxonrasib for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 18 May 2022: Trial registered, NCT05379985
  2. 31 May 2022: Trial started, NCT05379985
  3. 13 Nov 2023: Trial registered, NCT06128551
  4. 14 Nov 2023: Trial started, NCT06128551

The trials

NCT05379985: Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

State
Under way
Phase
Phase 1 and Phase 2
People
754 planned
Started
31 May 2022
Primary completion
31 May 2027
Arms
Experimental: RMC-6236
Results
None posted
  1. 18 May 2022: Trial registered
  2. 31 May 2022: Trial started

NCT06128551: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
534 planned
Started
14 Nov 2023
Primary completion
Dec 2028
Arms
Daraxonrasib Monotherapy
Results
None posted
  1. 13 Nov 2023: Trial registered
  2. 14 Nov 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.